1
|
Ouedraogo ZG, Janel C, Janin A, Millat G, Langlais S, Pontier B, Biard M, Lepage M, Francannet C, Laffargue F, Creveaux I. Relevance of Extending FGFR3 Gene Analysis in Osteochondrodysplasia to Non-Coding Sequences: A Case Report. Genes (Basel) 2024; 15:225. [PMID: 38397214 PMCID: PMC10888313 DOI: 10.3390/genes15020225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 01/31/2024] [Accepted: 02/07/2024] [Indexed: 02/25/2024] Open
Abstract
Skeletal dysplasia, also called osteochondrodysplasia, is a category of disorders affecting bone development and children's growth. Up to 552 genes, including fibroblast growth factor receptor 3 (FGFR3), have been implicated by pathogenic variations in its genesis. Frequently identified causal mutations in osteochondrodysplasia arise in the coding sequences of the FGFR3 gene: c.1138G>A and c.1138G>C in achondroplasia and c.1620C>A and c.1620C>G in hypochondroplasia. However, in some cases, the diagnostic investigations undertaken thus far have failed to identify the causal anomaly, which strengthens the relevance of the diagnostic strategies being further refined. We observed a Caucasian adult with clinical and radiographic features of achondroplasia, with no common pathogenic variant. Exome sequencing detected an FGFR3(NM_000142.4):c.1075+95C>G heterozygous intronic variation. In vitro studies showed that this variant results in the aberrant exonization of a 90-nucleotide 5' segment of intron 8, resulting in the substitution of the alanine (Ala359) for a glycine (Gly) and the in-frame insertion of 30 amino acids. This change may alter FGFR3's function. Our report provides the first clinical description of an adult carrying this variant, which completes the phenotype description previously provided in children and confirms the recurrence, the autosomal-dominant pathogenicity, and the diagnostic relevance of this FGFR3 intronic variant. We support its inclusion in routinely used diagnostic tests for osteochondrodysplasia. This may increase the detection rate of causal variants and therefore could have a positive impact on patient management. Finally, FGFR3 alteration via non-coding sequence exonization should be considered a recurrent disease mechanism to be taken into account for new drug design and clinical trial strategies.
Collapse
Affiliation(s)
- Zangbéwendé Guy Ouedraogo
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; (C.J.); (S.L.); (M.L.)
- Université Clermont Auvergne, CNRS, Inserm, iGReD, 63001 Clermont-Ferrand, France
| | - Caroline Janel
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; (C.J.); (S.L.); (M.L.)
| | - Alexandre Janin
- Unité Fonctionnelle Cardiogénétique, Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, 69677 Bron, France; (A.J.); (G.M.)
- CNRS UMR5261, INSERM U1315, Pathophysiology and Genetics of Neuron and Muscle, Institut Neuromyogène, Université Claude Bernard Lyon 1, 69008 Lyon, France
| | - Gilles Millat
- Unité Fonctionnelle Cardiogénétique, Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, 69677 Bron, France; (A.J.); (G.M.)
- CNRS UMR5261, INSERM U1315, Pathophysiology and Genetics of Neuron and Muscle, Institut Neuromyogène, Université Claude Bernard Lyon 1, 69008 Lyon, France
| | - Sarah Langlais
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; (C.J.); (S.L.); (M.L.)
| | - Bénédicte Pontier
- Service de Génétique Médicale, CHU Estaing, CHU Clermont-Ferrand, 63100 Clermont-Ferrand, France; (B.P.); (C.F.); (F.L.)
| | - Marie Biard
- Service de Radiologie Pédiatrique, CHU Estaing, CHU Clermont-Ferrand, 63100 Clermont-Ferrand, France;
| | - Mathis Lepage
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; (C.J.); (S.L.); (M.L.)
| | - Christine Francannet
- Service de Génétique Médicale, CHU Estaing, CHU Clermont-Ferrand, 63100 Clermont-Ferrand, France; (B.P.); (C.F.); (F.L.)
| | - Fanny Laffargue
- Service de Génétique Médicale, CHU Estaing, CHU Clermont-Ferrand, 63100 Clermont-Ferrand, France; (B.P.); (C.F.); (F.L.)
| | - Isabelle Creveaux
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; (C.J.); (S.L.); (M.L.)
| |
Collapse
|
2
|
Aubert-Mucca M, Janel C, Porquet-Bordes V, Patat O, Touraine R, Edouard T, Michot C, Tessier A, Cormier-Daire V, Attie-Bitach T, Baujat G. Clinical heterogeneity of NADSYN1-associated VCRL syndrome. Clin Genet 2023. [PMID: 36951206 DOI: 10.1111/cge.14328] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 03/06/2023] [Accepted: 03/12/2023] [Indexed: 03/24/2023]
Abstract
The NADSYN1 gene [MIM*608285] encodes the NAD synthetase 1 enzyme involved in the final step of NAD biosynthesis, crucial for cell metabolism and organ embryogenesis. Perturbating the role of NAD biosynthesis results in the association of vertebral, cardiac, renal, and limb anomalies (VCRL). This condition was initially characterized as severe with perinatal lethality or developmental delay and complex malformations in alive cases. Sixteen NADSYN1-associated patients have been published so far. This study illustrates the wide phenotypic variability in NADSYN1-associated NAD deficiency disorder. We report the clinical and molecular findings in three novel cases, two of them being siblings with the same homozygous variant and presenting with either a very severe prenatal lethal or a mild phenotypic form. In addition to an exhaustive literature, we validate the expansion of the spectrum of NAD deficiency disorder. Our findings indicate that NAD deficiency disorder should be suspected not only in the presence of the full spectrum of VCRL, but even a single of the aforementioned organs is affected. Decreased plasmatic levels of NAD should then strongly encourage the screening for any of the genes responsible for a NAD deficiency disorder.
Collapse
Affiliation(s)
- Marion Aubert-Mucca
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Toulouse, France
- Endocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France
| | - Caroline Janel
- Service de Biochimie et Génétique Moléculaire, CHU Gabriel Montpied, & Laboratoire AURAGEN, Clermont-Ferrand, France
| | - Valérie Porquet-Bordes
- Endocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France
| | - Olivier Patat
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Toulouse, France
| | - Renaud Touraine
- Service de Génétique Clinique, Chromosomique et Moléculaire, CHU-Hôpital Nord, & Laboratoire AURAGEN, Saint Étienne, France
| | - Thomas Edouard
- Endocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France
| | - Caroline Michot
- Service de Médecine Génomique des Maladies rares, AP-HP, Bone Diseases expert center, OSCAR network, ERN BOND, Hôpital Necker-Enfants-malades, Paris, France
| | - Aude Tessier
- Service de Médecine Génomique des Maladies rares, AP-HP, Bone Diseases expert center, OSCAR network, ERN BOND, Hôpital Necker-Enfants-malades, Paris, France
| | - Valérie Cormier-Daire
- Service de Médecine Génomique des Maladies rares, AP-HP, Bone Diseases expert center, OSCAR network, ERN BOND, Hôpital Necker-Enfants-malades, Paris, France
- Université Paris Cité, INSERM UMR 1163, Institut Imagine, Hôpital Necker Enfants Malades, Paris, France
| | - Tania Attie-Bitach
- Service de Médecine Génomique des Maladies rares, AP-HP, Bone Diseases expert center, OSCAR network, ERN BOND, Hôpital Necker-Enfants-malades, Paris, France
| | - Geneviève Baujat
- Service de Médecine Génomique des Maladies rares, AP-HP, Bone Diseases expert center, OSCAR network, ERN BOND, Hôpital Necker-Enfants-malades, Paris, France
| |
Collapse
|
4
|
Moradkhani K, Cuisset L, Boisseau P, Pichon O, Lebrun M, Hamdi-Rozé H, Maurin ML, Gruchy N, Manca-Pellissier MC, Malzac P, Bilan F, Audrezet MP, Saugier-Veber P, Fauret-Amsellem AL, Missirian C, Kuentz P, Egea G, Guichet A, Creveaux I, Janel C, Harzallah I, Touraine R, Goumy C, Joyé N, Puechberty J, Haquet E, Chantot-Bastaraud S, Schmitt S, Gosset P, Duban-Bedu B, Delobel B, Vago P, Vialard F, Gomes DM, Siffroi JP, Bonnefont JP, Dupont JM, Jonveaux P, Doco-Fenzy M, Sanlaville D, Le Caignec C. Risk estimation of uniparental disomy of chromosome 14 or 15 in a fetus with a parent carrying a non-homologous Robertsonian translocation. Should we still perform prenatal diagnosis? Prenat Diagn 2019; 39:986-992. [PMID: 31273809 DOI: 10.1002/pd.5518] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 06/07/2019] [Accepted: 06/28/2019] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Uniparental disomy (UPD) testing is currently recommended during pregnancy in fetuses carrying a balanced Robertsonian translocation (ROB) involving chromosome 14 or 15, both chromosomes containing imprinted genes. The overall risk that such a fetus presents a UPD has been previously estimated to be around ~0.6-0.8%. However, because UPD are rare events and this estimate has been calculated from a number of studies of limited size, we have reevaluated the risk of UPD in fetuses for whom one of the parents was known to carry a nonhomologous ROB (NHROB). METHOD We focused our multicentric study on NHROB involving chromosome 14 and/or 15. A total of 1747 UPD testing were performed in fetuses during pregnancy for the presence of UPD(14) and/or UPD(15). RESULT All fetuses were negative except one with a UPD(14) associated with a maternally inherited rob(13;14). CONCLUSION Considering these data, the risk of UPD following prenatal diagnosis of an inherited ROB involving chromosome 14 and/or 15 could be estimated to be around 0.06%, far less than the previous estimation. Importantly, the risk of miscarriage following an invasive prenatal sampling is higher than the risk of UPD. Therefore, we do not recommend prenatal testing for UPD for these pregnancies and parents should be reassured.
Collapse
Affiliation(s)
| | - Laurence Cuisset
- Laboratory of Genetics and Molecular Biology, Institute Cochin and Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | | | - Olivier Pichon
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - Marine Lebrun
- Service de Génétique-Laboratoire de Biologie Moléculaire, CHU-Hôpital Nord, Saint-Etienne, France
| | - Houda Hamdi-Rozé
- Department of Molecular Genetics and Genomics, CHU Rennes, Rennes, France
| | - Marie-Laure Maurin
- Service d'Histologie, Embryologie, Cytogénétique., Groupe Hospitalier Necker-Enfants Malades, Paris, France
| | - Nicolas Gruchy
- Service de Génétique, CHU Caen, Université Caen Normandie, Caen, France
| | | | - Perrine Malzac
- Département de Génétique Médicale, Assistance Publique- Hôpitaux de Marseille, Marseille, France
| | | | | | - Pascale Saugier-Veber
- Department of Genetics, Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen University Hospital, Rouen, France
| | - Anne-Laure Fauret-Amsellem
- Department of Genetics, Robert-Debré Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Chantal Missirian
- Département de Génétique Médicale, Assistance Publique- Hôpitaux de Marseille, Marseille, France
| | - Paul Kuentz
- Génétique Biologique Histologie, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Gregory Egea
- Laboratoire de Biologie Médicale GEN-BIO, Clermont-Ferrand, France
| | | | - Isabelle Creveaux
- Department of Biochemistry and Molecular Genetics, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Caroline Janel
- Department of Biochemistry and Molecular Genetics, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Ines Harzallah
- Service de Génétique-Laboratoire de Biologie Moléculaire, CHU-Hôpital Nord, Saint-Etienne, France
| | - Renaud Touraine
- Service de Génétique-Laboratoire de Biologie Moléculaire, CHU-Hôpital Nord, Saint-Etienne, France
| | - Carole Goumy
- Cytogénétique Médicale, CHU Estaing, Clermont-Ferrand, France.,U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, INSERM, Clermont-Ferrand, France
| | - Nicole Joyé
- Physiopathologie des Maladies Génétiques d'Expression Pédiatrique, Sorbonne Université, INSERM, Paris, France
| | - Jacques Puechberty
- Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | - Emmanuelle Haquet
- Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | | | | | - Philippe Gosset
- Diagnostic Préimplantatoire, Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Bénédicte Duban-Bedu
- Centre de Génétique Chromosomique, GH de l'Institut Catholique de Lille-Hopital Saint Vincent de Paul, Lille, France
| | - Bruno Delobel
- Centre de Génétique Chromosomique, GH de l'Institut Catholique de Lille-Hopital Saint Vincent de Paul, Lille, France
| | - Philippe Vago
- Cytogénétique Médicale, CHU Estaing, Clermont-Ferrand, France.,U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, INSERM, Clermont-Ferrand, France
| | - François Vialard
- Unité de Cytogénétique, CHI de Poissy St Germain en Laye, Poissy, France.,EA7404-GIG, UFR des Sciences de la Santé Simone Veil, UVSQ, Montigny-le-Bretonneux, France
| | - Denise Molina Gomes
- Unité de Cytogénétique, CHI de Poissy St Germain en Laye, Poissy, France.,EA7404-GIG, UFR des Sciences de la Santé Simone Veil, UVSQ, Montigny-le-Bretonneux, France
| | - Jean-Pierre Siffroi
- Physiopathologie des Maladies Génétiques d'Expression Pédiatrique, Sorbonne Université, INSERM, Paris, France
| | - Jean-Paul Bonnefont
- Service d'Histologie, Embryologie, Cytogénétique., Groupe Hospitalier Necker-Enfants Malades, Paris, France
| | - Jean-Michel Dupont
- Laboratoire de Cytogénétique, HUPC Hôpital Cochin, APHP; Université Paris Descartes, Paris, France
| | - Philippe Jonveaux
- Laboratoire de Génétique, CHRU Nancy, Inserm U1256, Université de Lorraine, Nancy, France
| | - Martine Doco-Fenzy
- Service de Génétique, CHU REIMS, EA3801, UFR de Médecine REIMS, Reims, France
| | - Damien Sanlaville
- Department of Genetics, Lyon University Hospitals, Lyon, France.,Claude Bernard Lyon I University; Lyon Neuroscience Research Centre, CNRS UMR5292, INSERM, Lyon, France
| | | |
Collapse
|